Sign up to save your podcasts
Or
Share Breaking News in Pharma and Biotech: Gilead's Yeztugo Approval, Biopharma Deal Premiums, BioNTech-CureVac Merger, and AI in Precision Oncology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Breaking News in Pharma and Biotech: Gilead's Yeztugo Approval, Biopharma Deal Premiums, BioNTech-CureVac Merger, and AI in Precision Oncology
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.
View all episodes
By Pharma and BioTech News
3.6
1111 ratings
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.
More shows like Pharma and BioTech Daily
View all
WSJ Tech News Briefing
1,642 Listeners
NPR News Now
14,194 Listeners
WSJ Your Money Briefing
1,715 Listeners
Planet Money
30,688 Listeners
Bloomberg Businessweek
439 Listeners
WSJ Minute Briefing
661 Listeners
Equity
339 Listeners
The Long Run with Luke Timmerman
121 Listeners
The Indicator from Planet Money
9,510 Listeners
The Readout Loud
316 Listeners
The Journal.
5,957 Listeners
BioCentury This Week
30 Listeners
Biotech Hangout
18 Listeners
The Wall Street Skinny
194 Listeners
WSJ's Take On the Week
127 Listeners